Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415947 | 0.79 | TSHR (0.36) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL5832355 | 0.79 | L3MBTL1 (0.33) | TSHR | |
| SCHEMBL19809264 | 0.79 | TSHR (0.36) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL5831676 | 0.78 | CA1 (0.34) | CA1CA2CA7CA9ESR1 | |
| SCHEMBL27707269 | 0.77 | ALDH1A1 (0.30) | TSHR | |
| SCHEMBL29416118 | 0.77 | HTR1B (0.36) | — | |
| SCHEMBL15302581 | 0.77 | HTR1B (0.36) | — | |
| SCHEMBL7236461 | 0.75 | ACHE (0.39) | TSHRACHECA1CA2CA7 | |
| SCHEMBL9067521 | 0.75 | ALDH1A1 (0.33) | — | |
| SCHEMBL11359141 | 0.75 | HTT (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7009015-B2 | Silane compounds with an ortho-substituted aromatic ring directly attached to the silicon atom useful as electron donors in Ziegler-Natta catalysts; makes propylene polymers with high degree of stereoblocks | BASELL TECHNOLOGY COMPANY BV (NL) | 2006-03-07 | — | — | US | disclosed |
| EP-1157045-B1 | ALPHA-OLEFIN POLYMERIZATION CATALYST SYSTEM WHICH CONTAINS AN AROMATIC SILANE COMPOUND | BASELL POLIOLEFINE SPA (IT) | 2004-10-20 | — | — | EP | disclosed |
| US-6723865-B2 | FOR PRODUCING STEREOBLOCK POLYPROPYLENE | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2004-04-20 | — | — | US | disclosed |
| US-20020143204-A1 | Alpha-olefin polymerization catalyst system which contains an aromatic silane compound | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2002-10-03 | — | — | US | disclosed |
| EP-1157045-A1 | ALPHA-OLEFIN POLYMERIZATION CATALYST SYSTEM WHICH CONTAINS AN AROMATIC SILANE COMPOUND | Basell Technology Company B.V. (NL) | 2001-11-28 | — | — | EP | disclosed |
| US-20010016635-A1 | Alpha-olefin polymerization catalyst system which contains an aromatic silane compound | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2001-08-23 | — | — | US | disclosed |
| WO-2001046272-A1 | ALPHA-OLEFIN POLYMERIZATION CATALYST SYSTEM WHICH CONTAINS AN AROMATIC SILANE COMPOUND | BASELL TECHNOLOGY COMPANY B.V. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143204-A1 | Alpha-olefin polymerization catalyst system which contains an aromatic silane compound | OSBP, OXER1, OCIAD1 | TSHR 4856/4885ACHE 2699/4885CA1 4018/4885 |
| US-20010016635-A1 | Alpha-olefin polymerization catalyst system which contains an aromatic silane compound | OSBP, OXER1, OCIAD1 | TSHR 4856/4885ACHE 2699/4885CA1 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.